The largest double-blind, placebo-controlled trial of EMTT on its own so far was published in late 2025. In 126 patients with knee osteoarthritis, rotator cuff enthesopathy or lumbar spondyloarthrosis, eight weekly sessions of active EMTT improved physical function and pain more than a sham treatment at 6 and 12 weeks. The trial is a real step forward for the evidence. It is also one trial from one center, with 12 weeks of follow-up and imperfect blinding.
What is EMTT?
Extracorporeal magnetotransduction therapy (EMTT) delivers a high-intensity, rapidly changing magnetic field through a loop applicator. It is not shockwave: there is no mechanical pressure pulse. Its proposed effects are on how cells in tendon, joint and bone tissue behave.
EMTT is also not the same as the low-intensity pulsed electromagnetic field (PEMF) devices sold for home use. The trial below used a field of 80 mT. A 2026 systematic review of EMTT and PEMF trials found that low-intensity protocols, below about 5 mT, often produced results indistinguishable from placebo or comparison treatments, while high-intensity protocols were more consistently associated with improvement. Results from one kind of device should not be assumed for the other.
Why this trial matters
Before it, most EMTT research was small, open-label (patients knew what they received), combined with other treatments, or done in the laboratory. That makes it hard to know how much of any improvement came from EMTT itself. A double-blind, placebo-controlled design is the standard way to answer that question, because neither patients nor assessors know who received the real treatment.
How the trial was done
Hollander and colleagues, in the Journal of Back and Musculoskeletal Rehabilitation, ran a single-center randomized trial.
- Patients: 126 adults with pain for more than six weeks from knee osteoarthritis (31), rotator cuff enthesopathy (43) or lumbar spondyloarthrosis, meaning wear-related (arthritic) changes in the small joints of the lower spine (52).
- Treatment: active EMTT at 80 mT, 8 Hz and 10,000 pulses per session, once a week for eight weeks, or a sham treatment.
- Medication: anti-inflammatory drugs were stopped before the trial. Only paracetamol or metamizole was allowed for pain relief.
- Main outcome: quality of life on the SF-12 questionnaire, which has a physical score and a mental score. Pain on a 0–10 scale was a secondary outcome.
The study measured how people felt and functioned. It did not include imaging or tissue measurements, so it cannot show what changed inside the joint or tendon.
What it found
| Measure | Active EMTT | Sham |
|---|---|---|
| Pain (0–10), start | 5.1 | 5.2 |
| Pain at 6 weeks | 2.8 | 4.3 |
| Pain at 12 weeks | 2.2 | 4.2 |
| SF-12 physical score at 6 weeks | 42.9 | 38.6 |
| SF-12 physical score at 12 weeks | 45.5 | 38.7 |
The differences in pain and physical function at 6 and 12 weeks were statistically significant (p < 0.001). Higher SF-12 physical scores mean better physical function. The mental score did not differ between groups. One reading of that pattern is that the benefit was specific to physical symptoms rather than a general sense of feeling better, though the trial was not designed to prove that.
Results were reported for each condition separately as well. Except for shoulder pain at six weeks, pain was lower with active EMTT at every time point in every group, and physical function scores were higher. The trial was sized for the whole group, not for each condition, so the separate results are less certain than the overall result. The knee group, with 31 patients, is the smallest.
Side effects
No serious adverse events were reported. Treatment was noticeably more uncomfortable with active EMTT:
- Skin redness: 49% of active-treatment patients versus 10% with sham.
- Pain during the session: 43% versus 18%.
- Pain the day after a session: similar in both groups (6% versus 10%).
Limits worth knowing
- One center, one trial. Results need to be repeated by other groups before they can be treated as settled.
- Short follow-up. Outcomes stopped at 12 weeks. Whether the improvement lasts is unknown.
- Blinding was not perfect. Asked which treatment they thought they had received, 59% of the active group and 46% of the sham group guessed correctly. The difference was not statistically significant, but the skin redness and discomfort of active treatment may have told some patients what they were getting.
- Industry involvement. The device manufacturer supplied the equipment, and one author reported a lecture fee from the company. That does not invalidate the results, but it is worth knowing.
- No tissue endpoints. The trial cannot say whether EMTT changed cartilage, tendon or bone.
Where it fits with the rest of the research
The trial is the strongest evidence so far for EMTT used alone. Most other clinical studies tested EMTT added to another treatment. The best of those, a 2018 trial in 86 people with rotator cuff tendinopathy, found that adding active EMTT to shockwave improved pain and function more than shockwave with sham EMTT; we cover it in EMTT alone or with shockwave?. How the trials fit together, and what is still missing, is summarized in how strong is the evidence for EMTT?. There is still no meta-analysis of EMTT alone.
How we use this research
The trial supports EMTT as a reasonable option for selected people with degenerative joint and tendon-attachment pain. It does not show that EMTT repairs cartilage or tendon, and it does not replace exercise and load management, which remain part of most plans. We examine first, and use EMTT, shockwave, both or neither based on what the exam finds. If you have a long-standing joint or tendon problem, book a new patient exam.
Sources
- Hollander K, Burgkart R, von Eisenhart-Rothe R, Vester J, Gerdesmeyer L. Extracorporeal magnetotransduction therapy (EMTT) for management of musculoskeletal disorders: a double-blind, placebo-controlled, randomised trial. Journal of Back and Musculoskeletal Rehabilitation. 2026;39(3):885-895. PMID 41313312. (link)
- Klüter T, Krath A, Stukenberg M, et al. Electromagnetic transduction therapy and shockwave therapy in 86 patients with rotator cuff tendinopathy: a prospective randomized controlled trial. Electromagnetic Biology and Medicine. 2018;37(4):175-183. PMID 30183430. (link)
- Leyva Martínez I, Ramírez Arteaga A, Martínez-Rojano H, et al. Contemporary advances (2015–2026) in extracorporeal electromagnetic transduction therapy and pulsed electromagnetic fields for musculoskeletal disorders: a systematic review of dosimetry and clinical response. Biomedicines. 2026;14(8):1731. PMID 42652114. (link)
